Clarivate Analytics Joins Accenture’s Life Sciences Ecosystem to Help Accelerate Innovation in Drug Discovery and Scientific Research

Clarivate Analytics, the global leader in providing trusted insights and analytics to accelerate the pace of innovation, has joined Accenture’s open partner ecosystem, which is designed to help independent software vendors (ISVs), specialized content providers, and life sciences companies team more effectively to advance drug discovery efforts and improve patient outcomes.

The ecosystem is an integral part of Accenture’s cloud-based informatics research platform, which helps life sciences organizations improve productivity, efficiency and innovation in drug discovery. Clarivate is working with Accenture to integrate its content into Accenture’s research platform and provide access to more robust insights that enable data-driven decision-making.

Read More:  JumpStart 2019: 10 Digital Transformation Trends At Your Fingertips

“Drug and device developers can gain even greater value from Clarivate’s expertly-managed content when it is included in a platform that contains their own data and research results,” says Mukhtar Ahmed, President, Life Sciences, Clarivate Analytics. “Our collaboration with Accenture will greatly enhance the ability to interpret data and derive new insights, which will help researchers to accelerate the pace of innovation. With this collaborative approach, Clarivate and Accenture are supporting the industry’s mission to improve human health.”

Read More:  What AI’s Lifespan Boost Will Mean for Healthcare Managers and Providers

The data and intelligence provided by Cortellis, the life sciences suite of solutions from Clarivate, will be accessible to companies within a common informatics framework that addresses core infrastructure requirements such as data ingestion and cleansing, security and IP management, request management workflow, enterprise search, data governance, and collaboration environments.  The scientifically-curated content in Cortellis includes more than 600,000 compounds, 2.3 million biological pathways and effects, comprehensive experimental results, clinical trial outcomes, and biomarkers intelligence.  These rich data sets provide critical context for researchers and complement the data they generate in support of clinical research, regulatory, manufacturing, marketing and portfolio strategy needs.

“We’re pleased to welcome Clarivate to the open partner ecosystem, and to be working closely with them to integrate their intelligence and analytics into our cloud-based research platform,” said Joe Donahue, a managing director in Accenture’s Life Sciences practice.  “We look forward to exploring opportunities to collaborate with them across our life sciences business to help mutual clients make better-informed decisions based on a more robust analytical foundation.”

Read More:  WORBLI Calls 2018 the Year of Substantive Growth in Blockchain and Predicts Global Expansion in 2019